A. Schroeder

发表

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Manish R. Patel, Charles J. Vaske, Joe Y. Chang, 2016, Journal for Immunotherapy of Cancer.

Avelumab and cetuximab as a therapeutic combination: An overview of scientific rationale and current clinical trials in cancer.

J. Becker, J. Bourhis, F. Ciardiello, 2021, Cancer treatment reviews.

Inhibiting the inhibitors: Development of the IAP inhibitor xevinapant for the treatment of locally advanced squamous cell carcinoma of the head and neck.

R. Ferris, M. Tahara, J. Schoenfeld, 2022, Cancer treatment reviews.

Avelumab in Combination With Cetuximab and Chemotherapy as First-Line Treatment for Patients With Advanced Squamous NSCLC

E. Felip, F. Ciardiello, G. Stojanović, 2023, JTO clinical and research reports.

Abstract 2269: ATR inhibitor M6620 enhances anti-tumor efficacy of the combination of the anti-PD-L1 antibody avelumab with platinum-based chemotherapy

P. Soulard, A. Blaukat, A. Zimmermann, 2019, Immunology.

A phase Ib study of the anti-CD47 antibody magrolimab with the PD-L1 inhibitor avelumab (A) in solid tumor (ST) and ovarian cancer (OC) patients.

C. Takimoto, A. Patnaik, G. Fleming, 2020 .

First-in-human phase Ib trial of M9241 (NHS-IL12) plus avelumab in patients with advanced solid tumors, including dose expansion in patients with advanced urothelial carcinoma

A. Ravaud, Y. Vugmeyster, M. Sznol, 2023, Journal for ImmunoTherapy of Cancer.

Digital Commons@Becker Digital

F. Saad, A. Ravaud, A. Armstrong, 2023 .

Digital Commons@Becker Digital

A. Ravaud, Y. Vugmeyster, M. Sznol, 2023 .

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Charles J. Vaske, Joe Y. Chang, Scott R. Presnell, 2016, Journal for ImmunoTherapy of Cancer.